Accuray (ARAY)
(Delayed Data from NSDQ)
$1.63 USD
-0.04 (-2.40%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.63 USD
-0.04 (-2.40%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth C Momentum B VGM
Zacks News
Accuray (ARAY) Reports Break-Even Earnings for Q3
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and 2.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar
by Sriparna Ghosal
Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.
Accuray (ARAY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) registers growth in Service revenues during fiscal Q2.
Accuray (ARAY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 600.00% and 4.96%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Releases Encouraging Breast Cancer Study Results
by Zacks Equity Research
Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.
Accuray (ARAY) Gets 510(k) Nod for ClearRT in TomoTherapy
by Zacks Equity Research
Accuray (ARAY) new innovative imaging solution is designed to provide cost effective and exceptional diagnostic quality image.
Accuray (ARAY) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Accuray (ARAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.
Accuray (ARAY) Is Up 1.82% in One Week: What You Should Know
by Zacks Equity Research
Does Accuray (ARAY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Accuray (ARAY) Inks Cancer Treatment Technology Delivery Deal
by Zacks Equity Research
Accuray's (ARAY) new deal with DHL Supply Chain will help in the delivery of advanced cancer treatment technology.
Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates
by Zacks Equity Research
Accuray (ARAY) registered growth in Service revenues in Q1.
Accuray (ARAY) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 100.00% and 10.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Accuray (ARAY) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health
3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings
by Sriparna Ghosal
These three MedTech stocks are expected to grow post their Q3 earnings release.
Idexx (IDXX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Robot-Assisted Surgery Gains Momentum Amid Coronavirus
by Trina Mukherjee
Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.
Accuray's Radixact With Synchrony Used in Japan Hospitals
by Zacks Equity Research
The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.
Accuray (ARAY) Down 16.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Accuray (ARAY) registered decline in Product and Service revenues in Q4
Accuray (ARAY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend
by Sriparna Ghosal
Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Coronavirus Spurs Growth for 3 Robotics-Assisted Surgery Stocks
by Sriparna Ghosal
In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.